JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Cells / Cell Lines

Anti-CD19 CAR-T Cells

SKU : BHC18200254

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	78171-1
Description	The anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3zeta; SIN Vector, Biohippo, #78601). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3zeta signaling domains. These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. Mycoplasma testing: The cells have been screened to confirm the absence of Mycoplasma species. Host Species: human Supplied as Each vial contains 2 x 10⁶ cells in 1 ml of CryoStor CS10)
Background	CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, which is a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B-precursor ALL (Acute lymphoblastic leukemia). In addition, CD19 was the target of the first approved CAR-T cell therapy.
Application	Positive control for anti-CD19 CAR-T cellsScreening inhibitors or activators of anti-CD19 CAR-T cytotoxicityDesign and optimize co-culture cytotoxicity assay
Shipping Temperature	-80°C (dry ice)
Note	Troubleshooting Guide: For all further questions, please email [email protected]. Warning: Avoid freeze/thaw cycles.Donors have been screened and determined negative for:- Hepatitis B (anti-HBc EIA, HBsAg EIA)- Hepatitis C (anti-HCV EIA)- Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)- Human T-Lymphotropic Virus (HTLV-I/II)- HIV-1/HCV/HBV- West Nile Virus- Trypanasoma cruziNote: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate biological safety level 2 precautions should be used.

Storage Stability	Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.

Product Manual	Datasheet

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHC18200254	78171-1	1 vial	$1754.50		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.